EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

IncobotulinumtoxinA for Upper Limb Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Trial

David M Simpson, Marta Banach, Jason Aldred, Jack Lee, William Ondo, Fernando Pagan, Anastasia Bagretsova, Gudrun Klein, Thorin L Geister, Irena Pulte, Mandar Jog iD

Toxins · 2026

DOI: 10.3390/toxins18100435 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Toxins, 2026. Verfasst von David M Simpson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Essential Tremor, Neuromuscular Agents, Upper Extremity. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merz (Germany), Merz Therapeutics GmbH, Frankfurt am Main, Germany.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This double-blind, placebo-controlled, phase II trial (NCT04766723) investigated the efficacy and safety of incobotulinumtoxinA (Xeomin®) in the treatment of essential tremor (ET) of the upper limb (UL). Adults with ET of the UL were randomized 2:1 (n = 78) and treated (n = 77) with intramuscular injections of incobotulinumtoxinA or placebo at semi-flexible doses into their motor-dominant arm. The primary endpoint was the change from baseline to week 6 in maximum tremor amplitude at wrist level. Baseline characteristics of treated patients were well matched across treatment arms. The primary endpoint was not met; maximum tremor amplitude at the wrist decreased from baseline to week 6 in both groups, with changes numerically favoring placebo (least squares mean treatment difference 0.21, p = 0.28). At week 6, compared with the placebo group, the incobotulinumtoxinA group had improvement in The Essential Tremor Rating Assessment Scale (TETRAS) performance dominant UL score (p = 0.006) and Quality of Life in ET (QUEST) total score (p = 0.073). However, these secondary outcomes must be interpreted descriptively as exploratory findings. Although the p-value and the 95% confidence interval including zero did not support statistical significance, the observed numerical treatment difference in change from baseline in QUEST total score suggests that the treatment effect may be consistent with the minimal clinically important difference in favor of incobotulinumtoxinA. Improvement in TETRAS Activities of Daily Living UL score was similar in both groups at week 6 (p = 0.933). IncobotulinumtoxinA was generally well tolerated. Treatment of UL ET with incobotulinumtoxinA did not show superiority over placebo for the primary endpoint. Secondary and other efficacy endpoints should therefore be viewed as exploratory, generating hypotheses suggesting potential improvements in TETRAS UL performance score and quality of life that require confirmation in further research. IncobotulinumtoxinA demonstrated a favorable safety profile without any new or unexpected safety concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AEssential TremorNeuromuscular AgentsUpper ExtremityAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDouble-Blind MethodInjections, IntramuscularQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

efficacyessential tremorincobotulinumtoxinAsafetyupper limb

Substanzen

Botulinum Toxins, Type AincobotulinumtoxinANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • Specjalistyczne Gabinety Sp. z o.o.2, plac Lasoty 4, 30-539 Kraków, Poland.
  • Selkirk Neurology, Spokane, WA 99202, USA.
  • MDDT Inc., London, ON N6G 0J3, Canada.
  • Houston Methodist Neurological Institute, Houston, TX 77030, USA.
  • Weill Cornell Medical School, Manhattan, New York, NY 10021, USA.

ORCID-Profile: Mandar Jog

Förderung

  • Merz (Germany)
  • Merz Therapeutics GmbH, Frankfurt am Main, Germany

Zitieren

APA

Simpson, D. M., Banach, M., Aldred, J., Lee, J., Ondo, W., Pagan, F., Bagretsova, A., Klein, G., Geister, T. L., Pulte, I., & Jog, M. (2026). IncobotulinumtoxinA for Upper Limb Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Trial. Toxins. https://doi.org/10.3390/toxins18100435

Vancouver

Simpson DM, Banach M, Aldred J, Lee J, Ondo W, Pagan F, et al. IncobotulinumtoxinA for Upper Limb Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Trial. Toxins. 2026. doi:10.3390/toxins18100435

BibTeX
@article{Simpson2026,
  author = {Simpson, David M and Banach, Marta and Aldred, Jason and Lee, Jack and Ondo, William and Pagan, Fernando and Bagretsova, Anastasia and Klein, Gudrun and Geister, Thorin L and Pulte, Irena and Jog, Mandar},
  title = {IncobotulinumtoxinA for Upper Limb Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled Trial},
  journal = {Toxins},
  year = {2026},
  doi = {10.3390/toxins18100435}
}
Kostenlos starten →